Abstract
Experimental geroscience has identified rapamycin as a top candidate for promoting healthy aging and longevity in mammals. As multiple independent studies have successfully reproduced the lifespan and healthspan promoting effects of rapamycin, the focus has shifted to possible translational use. While a promising compound, clinical use of rapamycin is limited by concerns of side effects associated with the drug. Studies aimed at defining optimal dosage regimen, delivery route, and formulation will allow for benefits to be maximized while reducing side effects.
Author supplied keywords
Cite
CITATION STYLE
Johnson, S. C., & Kaeberlein, M. (2016). Rapamycin in aging and disease: Maximizing efficacy while minimizing side effects. Oncotarget, 7(29), 44876–44878. https://doi.org/10.18632/oncotarget.10381
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.